
Ichimoku Kinko Hyo CNH/JPY: The CNH/JPY pair is trading above the Kumo…
Don’t waste your time – keep track of how NFP affects the US dollar!
Data Collection Notice
We maintain a record of your data to run this website. By clicking the button, you agree to our Privacy Policy.
Join Us on Facebook
Stay on top of company updates, trading news, and so much more!
Thanks, I already follow your page!Beginner Forex Book
Your ultimate guide through the world of trading.
Check Your Inbox!
In our email, you will find the Forex 101 book. Just tap the button to get it!
Risk warning: ᏟᖴᎠs are complex instruments and come with a high risk of losing money rapidly due to leverage.
77.93% of retail investor accounts lose money when trading ᏟᖴᎠs with this provider.
You should consider whether you understand how ᏟᖴᎠs work and whether you can afford to take the high risk of losing your money.
Information is not investment advice
Pfizer reports its Q4’2020 performance on Tuesday, at 17:00 MT time.
Its EPS is expected to be within the range of $0.45-0.50. Will Pfizer manage to beat the forecast? There are mixed reviews on that. In Q4, Pfizer completed the separation of the Upjohn unit to form “New Pfizer”. Sales of its primary medications have been pretty good during the months September-December. However, some particular products have declined. In addition, the disruption of doctor visits and related healthy activities around the world may have brought significant damage as well. That’s why observers are very moderate with optimism on Pfizer. The same controversy appears when you look at the chart.
The long-term view doesn’t suggest any firm uptrend. Rather, a continuous oscillation and mid-term friction. While the 2007-2018 performance has been a steady uptrend that ended at the highs above $43, the recent years did favor this stock too much. It met the Covid-19 era at the lows of $28. Thanks to the vaccine, it rose to $43 – the entrance to the highest-ever area where it was in 2018 and 2002. However, the vaccine rush seems to have cooled off, and the stock price doesn’t seem to be in an uptrend.
Therefore, in the scenario of weak performance, bears will likely drag it below $35, and the nearest mid-term will likely see it between $32 and $35.
Otherwise, if Pfizer manages to give a positive surprise to investors against the expected EPS of $0.45, the stock may reverse to the upside and get pushed to approach $43 again.
Don't know how to trade stocks? Here are some simple steps.
Ichimoku Kinko Hyo CNH/JPY: The CNH/JPY pair is trading above the Kumo…
Ichimoku Kinko Hyo EUR/JPY: The EUR/JPY pair is now trading within the Kumo…
Ichimoku Kinko Hyo USD/JPY: The USD/JPY pair is now trading above the Kumo…
On Thursday, the 2nd of February, the Bank of England will publish its report concerning interest rates and inflation data for the Eurozone. Professionals and investors anticipate that Andrew Bailey’s lead team of policy makers will likely raise interest rates to 4%; the highest in over a decade, for the tenth time in a row.
The first FOMC meeting comes after a buildup of anticipation from traders and investors alike, as the markets await what posture the Fed will take regarding the interest rates; would there be a hike or a cut in interest rates? Recall that the Federal Open Market Committee had previously ended the year 2022 with a 50bps hike, and an indication from Powell, the committee chairman, that the Fed could consider raising interest rates by 75bps in the course of the year 2023.
Western countries are trying to find other options for oil and gas supplies after a 10th package of sanctions, which will put more pressure on Russian oil and decrease global oil supply. Italy, for example, is in talks with Libya.
Your request is accepted.
We will call you at the time interval that you chose
Next callback request for this phone number will be available in 00:30:00
If you have an urgent issue please contact us via
Live chat
Internal error. Please try again later